EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder

Ashley F Slagle, Jay Constantine, Harvey Kushner, Shelli Graham, Ginger Constantine

The American Journal on Addictions · 2026

DOI: 10.1111/ajad.70202 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The American Journal on Addictions, 2026. Verfasst von Ashley F Slagle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Aspen Consulting, LLC, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Marijuana Abuse, Dronabinol, Gabapentin. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PleoPharma, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Cannabis withdrawal symptoms can be severe and protracted, significantly impeding the ability to abstain from cannabis use, resulting in failed quit attempts and relapse. This clinical trial evaluated safety and efficacy of PP‐01, a novel dual‑mechanism of action, investigational agent, for mitigating cannabis withdrawal symptoms in patients with cannabis use disorder (CUD).

Methods

This Phase 1b/2a randomized, double‐blind, placebo‐controlled, crossover, 5‐night, inpatient study evaluated efficacy and safety of PP‐01 (nabilone and gabapentin) in 14 adults with moderate to severe CUD. Participants with daily/near daily use of ≥1 gram/day of cannabis and a history of cannabis withdrawal were randomized to PP‐01 or placebo. Severity and bothersomeness of withdrawal symptoms were evaluated by patient daily diary. Mixed model repeated measures analysis of variance was used to compare mean differences between PP‐01 and placebo.

Results

PP‐01 significantly reduced severity ( p = .0222) and bothersomeness ( p = .0063) of cannabis withdrawal symptoms within 10 and 4 h post‐first dose of PP‐01, respectively. Sleep quality and cannabis cravings significantly improved following first dose through discharge. Objective withdrawal measures also statistically significantly improved. PP‐01 was well tolerated; adverse events (AEs) were mild in severity with no serious AEs. Discussion and Conclusions Investigational PP‐01 mitigated cannabis withdrawal symptoms in participants with moderate to severe CUD, was safe and well‐tolerated in this proof‐of‐concept study. Scientific Significance PP‐01 is intended as a potential treatment for cannabis withdrawal syndrome (CWS)/CUD, a serious and unmet need for which there is no Food and Drug Administration (FDA)‐approved medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Withdrawal SyndromeMarijuana AbuseDronabinolGabapentinHumansDouble-Blind MethodAdultFemaleMaleCross-Over StudiesMiddle AgedProof of Concept StudySeverity of Illness IndexYoung Adult

Substanzen

nabiloneDronabinolGabapentin

Autor:innen und Institutionen

  • Aspen Consulting, LLC, Denver, Colorado, USA.
  • PleoPharma, Inc, Phoenixville, Pennsylvania, USA.
  • Biomedical Computer Research Institute, Penn Valley, Pennsylvania, USA.

Förderung

  • PleoPharma, Inc.

Zitieren

APA

Slagle, A. F., Constantine, J., Kushner, H., Graham, S., & Constantine, G. (2026). Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder. The American Journal on Addictions. https://doi.org/10.1111/ajad.70202

Vancouver

Slagle AF, Constantine J, Kushner H, Graham S, Constantine G. Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder. The American Journal on Addictions. 2026. doi:10.1111/ajad.70202

BibTeX
@article{Slagle2026,
  author = {Slagle, Ashley F and Constantine, Jay and Kushner, Harvey and Graham, Shelli and Constantine, Ginger},
  title = {Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder},
  journal = {The American Journal on Addictions},
  year = {2026},
  doi = {10.1111/ajad.70202}
}
Kostenlos starten →